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Abstract
Background: Chloroquine (CQ) is utilized as both cure and prophylaxis to Plasmodium infection. In animal studies,
CQ administration to experimental animals is via intraperitoneal (i.p.) injection of a single dose that varies from
daily to several times per week. Such daily administration can be distressing to the animals and provoke aggressive
behaviors that may affect the immune responses of the animal and interfere with data read-outs.
Findings: We describe a novel, viable and efficacious prophylactic and curative administration route whereby
chloroquine is continuously supplied in the drinking water to experimental animals. The prophylactic effect is
robust and the curative effect against patent blood stage infection comparable to the traditional route of i.p.
administration. Continuous drinking water administration may decrease animal stress responses and thus improve
the reliability of experimental data.
Findings
Chloroquine (CQ) is a classic 4-aminoquinoline that dis-
plays rapid schizonticidal activity against the blood stages
of many Plasmodium species. Accumulating at high con-
centrations within the blood-stage digestive vacuole [1] it
forms non-covalent complexes with heme [2], interferes
with heme sequestration to the less toxic product hemo-
zoin and poisons the parasite via the accretion of such
drug-heme complexes [3]. Discovered in 1934 and intro-
duced into clinical practise in 1947 as both treatment and
primary prophylaxis to malaria disease, it remains the first
drug of choice in most sub-Saharan African countries
despite the emergence of resistant strains in the late 1950s
[4] harboring the Plasmodium falciparum chloroquine
resistance transporter (PfCRT) gene [5].
In the laboratory, CQ remains a useful tool, particularly
when studying the immunology of murine Plasmodium
infection. Since the onset of clinical symptoms are conco-
mitant with the infection of red cells, CQ is often admi-
nistered as prophylaxis so that the parasite infection
manifests within the liver stage but does not develop to
blood-stage infection and pathology [6,7]. The adminis-
tration of CQ to experimental animals in such studies is
in nearly all occasions via intraperitoneal (i.p.) injection
of a single dose that varies from daily to several times per
week. In large studies, the daily administration of i.p.
injections to large-scale-cohorts of mice can be time-con-
suming, distressing to the animals and provoke aggressive
behaviors that may affect the immune responses of the
animal and thus interfere with data read-outs [8,9]. Thus
we explored the oral administration route as a prophylac-
tic and curative means of controlling and eliminating
Plasmodium berghei ANKA infection in C57BL/6 mice
via continuous (and unstopped) administration in the
drinking water as a convenient, low-interference adminis-
tration method.
The water uptake of mice is between 4 and 7 ml per
day depending upon air temperature and humidity [10].
Based on this volume we calculated a concentration of
CQ salt of 0.288 mg/ml dissolved in normal tap water to
deliver a daily oral dose of 1.15 mg to 2.02 mg. This is
broadly comparable to the concentrations delivered i.p.,
which themselves vary from study to study [6,7]. A small
amount of glucose powder (approximately 15 g/l) was
dissolved in the CQ solution (hereafter referred to as
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encourage consumption. Once dissolved, the solution
was administered in tinted light-resistant bottles and
refreshed weekly. No other liquid source was available.
T ot e s tt h ec u r a t i v ee f f e c to fC Q - D Wa g a i n s tap r e -
established infection versus the traditional route of i.p.
administration, animals (n = 10) were injected with 10
6
parasitized P. berghei ANKA erythrocytes in the tail vein
i.v.. Two days later these animals had parasitemias of
1.5-2%. CQ was administered by CQ-DW (n = 5) and
by i.p. injection (n = 5) of 100 μl solution dissolved in
PBS at a concentration of 8 mg/ml. In both groups, an
immediate and clear inhibitory effect upon the parasite
infection could be observed the next day, with blood
stages undetectable by microscopic analysis day 3 post-
CQ-DW treatment. CQ-DW was maintained until day 7
post-treatment whereupon it was replaced with normal
water. Mice were observed for a further 30 days and no
parasites were detectable by microscopic examination of
Giemsa-stained blood smears (Figure 1a). Control mice
succumbed to experimental cerebral malaria at day 8
(Figure 1b).
To test the prophylactic efficacy of CQ-DW, a separate
group of animals (n = 25) was infected by intravenous
(i.v.) injection of 10,000 purified Plasmodium berghei
ANKA sporozoites in the tail vein and then normal
drinking water was replaced with CQ-DW in a test group
(n = 20) and not in the control group (n = 5). Mice were
monitored until day 30 post-infection by daily analysis of
blood smears stained with Giemsa. No parasites were
observed in the test group during this period and control
mice became patent at days 4 - 5 (Figure 2). Upon repla-
cing CQ-DW with normal water, test mice were divided
into a further two groups. One test group (n = 10) was
challenged intravenously with 10
6 parasitized erythro-
cytes some five days after CQ-DW replacement and a
second control group (n = 10) was monitored. Blood
infection remained negative in the control group during
a further observation period of 30 days. In the test group,
mice were found to be susceptible to re-infection, with
parasites observed by Giemsa stain 24 hours post-chal-
lenge (data not shown).
Thus CQ-DW offers a convenient and robust method
for chloroquine treatment and prophylaxis in experimental
murine Plasmodium infection protocols. Over the course
of the experiments we did not observe any adverse effects
of continuous CQ treatment on the experimental animals.
Of additional note is that, unlike pyrimethamine-drinking
water preparations that produce a rancid odor and is see-
mingly associated with a reduction in consumption
volumes to minimal levels (unpublished own observa-
tions), animals are apparently satisfied to drink CQ-DW,
as we observed no change in drinking patterns or habits
between normal and CQ-DW administration. Also, it is
worth noting that there is a “point of no return” in CQ-
DW administration, since in animals with advanced
blood-stage infections and such debilitating malarial symp-
toms that they are incapable of liquid consumption, or
show significant lethargy or coma, the nature of “self-
administration” of CQ-DW is nullified. Additionally, one
inherent limitation to this means of administration is that
dosage will vary between individual animals depending
upon volume consumed. However, for the purpose of
maintaining prophylaxis or curing patent infection, despite
potential minor variability in exact dosage, our work
demonstrates that CQ-DW administration is efficacious,
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Figure 1 CQ-DW has a curative effect similar to i.p. administration in experimental animals. C57BL/6 mice (n = 20) were infected with 10
6
parasitized erythrocytes by i.v. injection at day 0. At day 2 post-infection, and thereafter daily, mice were administered chloroquine drinking
water preparation (CQ-DW) or i.p. injection of chloroquine (CQ i.p.). Parasitemia percentage was calculated by Giemsa stain of blood smears (A)
and animal survival was noted (B).
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existing patent parasitemias comparable to the established
route of i.p. administration. When considering the applic-
ability of such a method to humans in endemic areas we
must be highly cautious, due to considerations such as
parasite resistance and the toxic effects associated with
CQ treatment [11,12]. However, despite this, it is concei-
vable that the administration of individual doses of chloro-
quine via a dissolving seltzer tablet in water may be a
favourable dispensing method over tablets, much like the
syrup preparations that are commonly prescribed for
infants and young children [13]. Moreover, in the labora-
tory mouse, it is an efficacious and viable experimental
protocol that saves time for the researcher and improves
animal welfare standards, perhaps in turn improving the
reliability of experimental data.
Ethics Statement
All animal experiments were performed according to
FELASA category B and GV-SOLAS standard guide-
lines. Animal experiments were approved by German
authorities (Regierungspräsidium Karlsruhe, Germany), §
8 Abs. 1 Tierschutzgesetz (TierSchG).
List of abbreviations used
CQ: Chloroquine salt; CQ-DW: Drinking water supplemented with
chloroquine.
Acknowledgements
We thank Thomas Jänisch and members of the IBF Heidelberg for
discussions. We gratefully acknowledge support from the Heidelberg
University School of Medicine and the German Federal Ministry of Economy
and Technology (BMWI, Exist-Forschungstransfer).
Author details
1Department of Infectious Diseases, Parasitology Unit, Heidelberg University
School of Medicine, Im Neuenheimer Feld 324, D 69120 Heidelberg,
Germany.
2Angelika-Lautenschläger-Kinderklinik, Zentrum für Kinder-und
Jugendmedizin, Heidelberg University School of Medicine, Im Neuenheimer
Feld 430, D 69120 Heidelberg, Germany.
Authors’ contributions
Experiments conceived by MDL, JP and AKM. The manuscript was written by
MDL and AKM. The authors read and approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 24 May 2011 Accepted: 28 July 2011 Published: 28 July 2011
References
1. Yayon A, Cabantchik ZI, Ginsburg H: Susceptibility of human malaria
parasites to chloroquine is pH dependent. Proc Natl Acad Sci USA 1985,
82:2784-2788.
0 1 2 3 4 5 6 7 8 9
0
10
20
30
40
50
60
70
80
90
100
Control
CQ-DW
28 29 30
Days post-infection
B
l
o
o
d
 
s
t
a
g
e
 
s
t
e
r
i
l
i
t
y
 
%
Figure 2 CQ-DW has a prophylactic effect in experimental animals. C57BL/6 mice (n = 25) were infected with 10,000 sporozoites by i.v.
injection at day 0. Mice were immediately administered chloroquine drinking water preparation (CQ-DW). “Blood stage sterility” was assessed by
Giemsa stain of blood smears, with non-sterility diagnosed upon the irrefutable detection of two parasites per slide.
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